Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filgrastim + alemtuzumab
- Development stage
- Phase 2
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Filgrastim + alemtuzumab is a combination therapy consisting of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), and alemtuzumab, a monoclonal antibody targeting CD52. Filgrastim stimulates the production of neutrophils to reduce the risk of infection during periods of neutropenia, while alemtuzumab depletes lymphocytes by binding to CD52 on their surface, leading to cell lysis via antibody-dependent cellular cytotoxicity and complement-mediated lysis. This combination has been investigated primarily in hematologic malignancies such as refractory chronic lymphocytic leukemia (CLL) and in conditioning regimens for stem cell transplantation in severe combined immunodeficiency (SCID). The rationale for combining these agents is to mitigate the profound neutropenia caused by alemtuzumab with filgrastim support; however, studies have reported significant infectious complications including cytomegalovirus reactivation and delayed neutropenia[1][6].
- Brand names
- Neupogen (for filgrastim)Nivestym (filgrastim-aafi)Releuko (filgrastim-ayow)Zarxio (filgrastim-sndz)Granix (tbo-filgrastim)
- Other names
- anti-CD52 antibody + granulocyte-colony stimulating factor
02
Targets
CD52 (CD52 Antigen)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on filgrastim + alemtuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filgrastim + alemtuzumab.